Compare · ABT vs ANIP
ABT vs ANIP
Side-by-side comparison of Abbott Laboratories (ABT) and ANI Pharmaceuticals Inc. (ANIP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ANIP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 115.7x ANIP ($1.74B).
- ABT has been more active in the news (8 items in the past 4 weeks vs 7 for ANIP).
- ABT has more recent analyst coverage (25 ratings vs 12 for ANIP).
- Company
- Abbott Laboratories
- ANI Pharmaceuticals Inc.
- Price
- $116.11-0.50%
- $75.73+1.73%
- Market cap
- $200.95B
- $1.74B
- 1M return
- -
- -3.36%
- 1Y return
- -
- -17.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest ANIP
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $37,740 worth of shares (500 units at $75.48) as part of a pre-agreed trading plan, decreasing direct ownership by 0.67% to 74,424 units (SEC Form 4)
- SVP, GENERICS Gutwerg Ori sold $243,474 worth of shares (3,162 units at $77.00), decreasing direct ownership by 4% to 75,534 units (SEC Form 4)
- SEC Form 10-Q filed by ANI Pharmaceuticals Inc.
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
- SVP & CFO Carey Stephen P. sold $231,876 worth of shares (2,850 units at $81.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,693 units (SEC Form 4)
- ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith covered exercise/tax liability with 2,466 shares, decreasing direct ownership by 3% to 74,924 units (SEC Form 4)